AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read

IDACORP, Inc. Stock 12‑Month Price Target Cut to $154.29, Implies 14% Upside

IDACORP's average stock price target was reduced from $156.86 to $154.29 by 7 analysts, with a range of $143 to $171. This implies a 14% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 9 analysts.

Original reporting
tradingview.com
Published Oct 12, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IDACORP, Inc. Stock 12‑Month Price Target Cut to $154.29, Implies 14% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade may trigger short‑term selling pressure, but the consensus rating stays positive, limiting downside.

02

Market read

The news is a modest analyst target cut with limited market impact.

03

What to watch

Potential upcoming product launches or contract wins not reflected in the target revision.

Relevance 5/10Novelty 4/10Timing: post‑market release

Background

IDACORP is a micro‑cap industrial company; analyst consensus remains a Buy despite the slight target reduction.

Market effects

Sector

Minimal; the target change is company‑specific and does not affect the broader sector.

Regional

None; the news is confined to IDACORP investors.

Global

None

Counterpoint

What could challenge this read

Some investors may view the modest cut as an opportunity if they believe the stock is still undervalued.

Key entities

  • Company
    IDACORP, Inc.

    Subject of the price‑target revision.

Read at source← All news

Related articles

JUL 30
$IDAMedAI 8/10

IDACORP Q2 Profit Rises, Lifts FY26 Earnings Guidance

IDACORP reported Q2 net income of $102.6 million, or $1.79 per share, up from $95.8 million, or $1.76 per share a year earlier, citing customer growth and higher rates. Retail revenues per MWh fell to $27.5 from $44.0. For FY2026, it raised the lower end of EPS guidance to $6.30-$6.45 from $6.25-$6.45.

rttnews.com4 min
JUL 30
$IDAMed

IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range

IDACORP INC (IDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 July 30, 2026 IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range BOISE, Idaho--IDACORP, Inc. (NYSE: IDA) reported second quarter 2026 net income attributable to IDACORP of $102.6 million, or $1.79 per diluted share, co

SEC EDGAR 8-K6 min
OCT 12
$TRAXMedAI 8/10

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics (TRAX) reported positive results from a Phase Ib study of ANB033 for celiac disease, showing significant symptom reduction and fewer adverse events compared to placebo. The company plans to present results at ICDS in November and expects cohort two data in Q1 2027. ANB033 targets both IL-15 and IL-2, differentiating it from other therapies. The FDA has granted Fast Track designation, and late-stage trials are anticipated in 2027.

finance.yahoo.com2 min